Loading
Life sciences · Journal article
Journal of Nanobiotechnology · October 11, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Therapy-induced senescence (TIS) has emerged as an important contributor to treatment resistance and poor prognosis in clinical cancer therapy. Senescence initially acts as a tumor-suppressive mechanism by enforcing stable cell-cycle arrest, while the senescence-associated secretory phenotype (SASP) promotes the formation of pro-tumorigenic microenvironment, ultimately leading to therapeutic resistance and tumor relapse. Precise detection and targeted elimination of TIS have emerged as an important focus in cancer treatment. In this review, we first summarize tumor-specific fluorescent probes for senescence detection, including enzyme-responsive, non-enzymatic, dual-responsive, and theranostic platforms. We further discuss current senolytic approaches, including classical Bcl-2 family inhibitors, dasatinib-quercetin combinations, and emerging senolytic strategies. In addition, we summarize the cutting-edge senolytic regimens that synergize with chemotherapy, radiotherapy, photothermal therapy, and immunotherapy. Finally, we highlight the key challenges and future perspectives for clinical translation and application.